Genomic Health Inc. Message Board
-
What is important to notice is that Insiders control 53% and going private is a possibility.The Bakers are M&A artists but maybe they'll make an exception in this case since the genomic market is expected to grow to 25 B
-
that is so 90's .
companies don't do that anymore.Up55% took profits, -
cash in.The library will be stifled in the future
-
For $3850 a test the insurance companies will soon make it mandatory. The market is just getting started. Prostate is off ramp much more quickly than Breast and colon because of the unnecessary spending
- Reply to
Company has no current plans to sell Common Stock pursuant to the registration statement.
by terry_amln •May 13, 2013 5:40 PMThere was no "offering". There was simply an update on the original that was set to expire July 13.
- Reply to
10Q Launch of Prostate test and ...."consolidation " read
by terry_amln •May 7, 2013 5:44 PMnow why would they do a thing like that?
-
3 4 ?5 times? current price? The longer the company can hold out.
Prostate diagnostic is larger than breast cancer and colon cancer in the number of unnecessary surgeries COMBINED. The AAPL of genomic innovation. Stock is cheap -
8:01AM Genomic Health announces publication of second positive validation of oncotype DX colon cancer test confirming its value beyond conventional markers (GHDX) 28.85 : Co announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX? colon cancer test in stage II colon cancer patients. The findings provide further confirmation that the Oncotype DX Recurrence Score (RS) results improve the ability to differentiate high recurrence risk disease from low, beyond conventional factors such as T-stage, mismatch repair (MMR) status, nodes examined, grade and lymphovascular invasion.
-
almost daily Management cashing in;yesterday Cole@ 1.33
-
The options are priced high for good reason
30.0 Put 1.45 1.80 2.00 0.00 0 101
35.0 Put 6.20 6.80 6.55 0.00 0 27